Practical Management of Patients in Advanced NSCLC: Cisplatin or Carboplatin Combination Therapies



As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this E-Learning module allow you to discuss issues which challenge the equivalence of two platinum compounds (cis- and carboplatin) in the treatment of patients with advanced non-small cell lung cancer (NSCLC)? (1-not at all; 5-a lot)

2. Did your undertaking of this E-Learning module allow you to understand the pharmacology of platinum compounds and how it impacts on the management issues in solid tumors and especially NSCLC? (1-not at all; 5-a lot)

3. Did your undertaking of this E-Learning module provide clinical practice recommendations for the selection of platinum compound based on expected toxicity profile, patient organ function, patient comorbidities, and companion drug(s)? (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-completely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestions to improve future ESMO E-Learning material, please write in the box below: